trending Market Intelligence /marketintelligence/en/news-insights/trending/3hTMR8ILjrCj2vyWB7cWAQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

GeneNews launches test for breast cancer risk assessment

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


GeneNews launches test for breast cancer risk assessment

GeneNews Ltd. launched BreastSentry, a blood-based biomarker test to assess risk of breast cancer.

The test, launched via the company's Virginia clinical reference lab Innovative Diagnostics Laboratory, measures the fasting plasma levels of two blood biomarkers which are "highly predictive" of the risk for developing breast cancer, GeneNews said.

The test is intended for use by women who are at average risk and have no family of history of breast cancer. The company said BreastSentry is especially suited for the 50% of U.S. women with dense breast tissue, who cannot rely solely on mammography to detect whether they have breast cancer.